Cohance Lifesciences has entered into an agreements with Chromo Laboratories India for the sale of the assets pertaining to its standalone Clinical Research and Bio-analytical unit (CR Bio), for a consideration of Rs 16 crore. The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations. The said transaction is expected to be completed in Q2 FY26, subject to satisfaction of customary closing conditions under the said agreements.
Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.
